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Abstract: N1-methylnicotinamide (N1-MN) and N1-methyl-2-pyridone-5-carboxamide (2Py) are
successive end products of NAD+ catabolism. N1-MN excretion in 24-h urine is the established
biomarker of niacin nutritional status, and recently shown to be reduced in renal transplant recipients
(RTR). However, it is unclear whether 2Py excretion is increased in this population, and, if so, whether
a shift in excretion of N1-MN to 2Py can be attributed to kidney function. Hence, we assessed the 24-h
urinary excretion of 2Py and N1-MN in RTR and kidney donors before and after kidney donation, and
investigated associations of the urinary ratio of 2Py to N1-MN (2Py/N1-MN) with kidney function, and
independent determinants of urinary 2Py/N1-MN in RTR. The urinary excretion of 2Py and N1-MN
was measured in a cross-sectional cohort of 660 RTR and 275 healthy kidney donors with liquid
chromatography-tandem mass spectrometry (LC-MS/MS). Linear regression analyses were used to
investigate associations and determinants of urinary 2Py/N1-MN. Median 2Py excretion was 178.1
(130.3–242.8) µmol/day in RTR, compared to 155.6 (119.6–217.6) µmol/day in kidney donors (p < 0.001).
In kidney donors, urinary 2Py/N1-MN increased significantly after kidney donation (4.0 ± 1.4 to
5.2 ± 1.5, respectively; p < 0.001). Smoking, alcohol consumption, diabetes, high-density lipoprotein
(HDL), high-sensitivity C-reactive protein (hs-CRP) and estimated glomerular filtration rate (eGFR)
were identified as independent determinants of urinary 2Py/N1-MN in RTR. In conclusion, the 24-h
urinary excretion of 2Py is higher in RTR than in kidney donors, and urinary 2Py/N1-MN increases
after kidney donation. As our data furthermore reveal strong associations of urinary 2Py/N1-MN
with kidney function, interpretation of both N1-MN and 2Py excretion may be recommended for
assessment of niacin nutritional status in conditions of impaired kidney function.
Keywords: N1-methyl-2-pyridone-5-carboxamide; N1-methylnicotinamide; urinary excretion; renal
transplantation; kidney function; biomarker; niacin status; tryptophan; vitamin B3
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1. Introduction
Niacin, or vitamin B3, is the precursor of the nicotinamide nucleotide coenzyme NAD+.
An adequate niacin status is vital to provide reducing equivalents for energy metabolism, and
substrates of NAD+ consuming enzymes, including adenosine diphosphate (ADP)-ribosyl transferases
and deacetylases, that transfer ADP-ribose moieties from NAD+ and NADP+ [1,2].
Niacin nutritional status is most commonly assessed by the 24-h urinary excretion of
N1-methylnicotinamide (N1-MN) as a breakdown product of NAD+, and recommended as such
by authorities, including the WHO and the European Food Safety Authority (EFSA) [3,4]. However,
N1-methyl-2-pyridone-5-carboxamide (2Py) is the end product of NAD+ catabolism, after aldehyde
oxidase (AOX1)-dependent oxidation of N1-MN (Figure 1) [5,6]. Although the 24-h urinary excretion
of N1-MN has shown the most sensitive response to oral test doses of niacin equivalents [3,7], excretion
of 2Py, whether or not combined with that of N1-MN, has also been implicated for the assessment of
niacin status [8–11].
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2.1. Study Population
This cross-sectional study was based on a well-characterized, single-center cohort of 707 RTR (aged
≥18 years) who visited the outpatient clinic of the University Medical Center Groningen, Groningen,
the Netherlands, between 2008 and 2011, with a functioning graft for at least 1 year and no history of
alcohol and/or drug abuse [15–17]. As a control group, 367 healthy kidney donors were included who
participated in a screening program before kidney donation, and of whom biomaterial was collected
before and, after declared eligible, 3 months after kidney donation. Exclusion of subjects with missing
biomaterial or niacin supplementation use left 660 RTR and 275 kidney donors, of which 85 underwent
donor nephrectomy during the inclusion period, eligible for statistical analyses. Signed informed
consent was obtained from all participating subjects and the study protocol was approved by the
institutional review board (METc 2008/186) adhering to the Declaration of Helsinki. This study included
the same cohort of 660 RTR and 275 kidney donors for data collection as reported previously [12].
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2.2. Data Collection and Measurements
Participants were instructed to collect a 24-h urine sample on the day before their morning visit to
the outpatient clinic, and to fast overnight for 8 to 12 h. Urine samples were collected under oil, and
chlorhexidine was added as an antiseptic agent. Fasting blood samples were drawn after completion of
the urine collection. Laboratory measurements were performed directly with spectrophotometric-based
routine clinical laboratory methods (Roche Diagnostics, Rotkreuz, Switzerland). Body composition
and hemodynamic parameters were measured according to a previously described, strict protocol [15].
Diabetes was diagnosed if fasting plasma glucose was ≥7.0 mmol/L or antidiabetic medication was
used. Proteinuria was diagnosed if total urinary protein excretion was ≥0.5 g/day as measured by a
biuret reaction-based assay (MEGA AU510; Merck Diagnostica, Darmstadt, Germany).
Dietary intake was assessed with a validated semi-quantitative food frequency questionnaire
(FFQ) [18,19]. The self-administered questionnaire was filled out at home and inquired about 177 food
items over the last month. During the outpatient clinic visit, the FFQ was checked for completeness by a
trained researcher and inconsistent answers were verified with the participant. The FFQ was validated
for RTR as previously reported [16]. Dietary data were converted into daily nutrient intake using the
Dutch Food Composition Table of 2006 [20]. Intake of niacin equivalents was calculated by adding up
niacin and one-sixtieth of tryptophan intake. Subjects who were using niacin supplementation were
excluded. Smoking behavior was assessed with a separate questionnaire [21]. Data on medication and
vitamin supplements use, and medical history were obtained from medical records [21].
The estimated glomerular filtration rate (eGFR) was calculated by the combined creatinine and
cystatin C-based Chronic Kidney Disease Epidemiology Collaboration equation [22], which has shown
to be the most accurate equation in RTR [23]. The glomerular filtration rate (GFR) was measured by
infusion of 125I-Iothalamate as described previously [24].
2.3. Assessment of 2Py and N1-MN Excretion
Measurement of 2Py and N1-MN concentrations was performed with a validated liquid
chromatography (Luna HILIC column; Phenomenex, Torrance, CA, USA) isotope dilution-tandem
mass spectrometry (Quattro Premier; Waters, Milford, MA, USA) (LC-MS/MS) method, as described
previously [25], with the addition of N1-methyl-2-pyridone-5-carboxamide-d3 in acetonitrile as an
internal standard. The 24-h urinary excretion of 2Py and N1-MN (µmol/day) was obtained by
multiplying concentrations (µmol/L) by total urine volume calculated from weight (L/day).
2.4. Statistical Analysis
Data are presented as the mean± SD, median (IQR) and absolute number (percentage) for normally
distributed, skewed and nominal data, respectively. Assumptions for normality were checked by
visual judgments of the corresponding frequency distribution and Q-Q plot.
Baseline characteristics of RTR and the total cohort of kidney donors were compared by means of
t, Mann–Whitney, and Chi-Square tests, of which age, sex, body surface area, N1-MN excretion and
eGFR have been reported previously [12]. Crude associations of 2Py and N1-MN excretion with intake
of niacin equivalents were investigated with linear regression analyses. Characteristics of kidney
donors before and after kidney donation were compared by means of paired samples t and Wilcoxon
signed rank tests.
Linear regression analyses were used to investigate associations of urinary 2Py/N1-MN with
kidney function in RTR and kidney donors, with additional adjustments for age and sex. Effect
modification between either age or sex and kidney function with urinary 2Py/N1-MN was assessed by
including the corresponding cross product term in the linear regression model.
Linear regression analyses were furthermore employed to investigate cross-sectional associations
of urinary 2Py/N1-MN with baseline variables in RTR. Variables were 2-base log-transformed when
assumptions of normality and homogeneity of variance of the residuals, based on visual judgement of
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P-P and scatter plots, respectively, were not met. Multivariable linear regression analyses were used
to identify determinants of urinary 2Py/N1-MN, by entering terms with p-value <0.1 in univariable
analysis, and eliminating the least significant term stepwise until the remaining terms contributed
significantly to the model.
For all statistical analyses, a two-sided p-value of less than 0.05 was considered to indicate
statistical significance and SPSS Statistics version 23.0 (IBM, Armonk, NY, USA) was used as software.
3. Results
3.1. Excretion of 2Py in Kidney Donors and RTR
The total cohort consisted of 660 stable RTR (57% male; mean age 53.0 ± 12.7 years), included
at a median time of 5.6 (2.0–12.0) years after transplantation, and 275 healthy kidney donors (41%
male; mean age 53.3 ± 10.7 years) (Table 1). Differences in the 24-h urinary excretion of 2Py and
N1-MN and kidney function are shown in Table 1. 2Py excretion was higher in RTR than in kidney
donors (178.1 (130.3–242.8) versus 155.6 (119.6–217.6) µmol/day, respectively; p < 0.001), while N1-MN
excretion was lower in RTR than in kidney donors (22.0 (15.8–31.8) versus 41.4 (31.6–57.2) µmol/day,
respectively; p < 0.001). Kidney function was significantly lower in RTR than in kidney donors (eGFR:
45.8 ± 18.7 versus 91.0 ± 14.2 mL/min/1.73 m2, respectively; p < 0.001 and GFR: 52.4 ± 17.4 versus
82.3 ± 29.7 mL/min/1.73 m2, respectively; p < 0.001). Urinary 2Py/N1-MN was significantly higher in
RTR than in kidney donors (8.7 ± 3.8 versus 4.0 ± 1.4, respectively; p < 0.001), while the sum of 2Py and
N1-MN excretion was similar (198.3 (155.9–269.4) versus 203.7 (149.4–274.7) µmol/day, respectively;
p = 0.98). The urinary fraction of 2Py was higher in RTR than in kidney donors (89.1% (86.4%–91.3%)
versus 79.0% (75.6%–82.1%), respectively; p < 0.001), and that of N1-MN was lower (10.9% (8.7%–13.6%)
versus 21.0% (17.9%–24.4%), respectively; p < 0.001). The 24-h urinary excretion of 2Py, N1-MN and
the sum of 2Py and N1-MN, but not urinary 2Py/N1-MN, were directly associated with intake of niacin
equivalents (Table S1).
3.2. Excretion of 2Py and N1-MN before and after Kidney Donation in Kidney Donors
The 24-h urinary excretion of 2Py and N1-MN and kidney function in 85 kidney donors before
and after kidney donation are shown in Table 1 and Figure 2. At a median time of 1.64 (1.61–1.87)
months after kidney donation, 2Py excretion did not change significantly (152.8 (124.4–215.1) to
161.7 (116.6–227.8) µmol/day, respectively; p = 0.31), while N1-MN decreased (40.9 (31.0–58.2) to
32.5 (23.4–44.0) µmol/day, respectively; p < 0.001). Kidney function decreased significantly after
kidney donation (eGFR: 92.8 ± 13.9 to 60.1 ± 12.1 mL/min/1.73 m2, respectively; p < 0.001 and GFR:
103.7 ± 16.7 to 65.3 ± 10.4 mL/min/1.73 m2, respectively; p < 0.001). Urinary 2Py/N1-MN increased
after kidney donation (4.0 ± 1.4 to 5.2 ± 1.5, respectively; p < 0.001), while the sum of 2Py and
N1-MN excretion did not change (198.3 (162.3–270.8) to 189.7 (141.9–271.6) µmol/day, respectively;
p = 0.90). The urinary fraction of 2Py increased after kidney donation (78.3% (75.5%–81.8%) to 83.5%
(80.0%–86.0%), respectively; p < 0.001), and that of N1-MN decreased (21.7% (18.2%–24.5%) to 16.5%
(14.0%–20.0%), respectively; p < 0.001).
3.3. Associations of Urinary 2Py/N1-MN with Kidney Function
Urinary 2Py/N1-MN was associated with kidney function in RTR (eGFR: β = −0.40; p < 0.001 and
GFR: β = −0.39; p < 0.001) and the total cohort of kidney donors (eGFR: β = −0.17; p = 0.03 and GFR:
β = −0.20; p = 0.003), but not in the pre- (eGFR: β = −0.01; p = 0.94 and GFR: β = −0.02; p = 0.89) and
post-donation subgroups of kidney donors (eGFR: β = −0.11; p = 0.42 and GFR: β = 0.15; p = 0.27), with
adjustment for age and sex (Table 2). No significant interaction between either age or sex with kidney
function was found in the association with urinary 2Py/N1-MN in RTR and kidney donors.
J. Clin. Med. 2020, 9, 437 5 of 14
Table 1. Excretion of 2Py and N1-MN and kidney function in RTR and kidney donors before and after kidney donation 1.
RTR Kidney Donors Population Kidney Donors Paired
Variable n = 660 n = 275 Difference n = 85 Difference
Total Cohort Total Cohort p-Value 2 Pre-Donation Post-Donation p-Value 3
Age, years 53.0 ± 12.7 53.3 ± 10.7 0.68 52.2 ± 10.5 52.6 ± 10.4 <0.001
Male, n (%) 379 (57) 112 (41) 0.001 43 (51) 43 (51) -
Body surface area, m2 1.9 ± 0.2 1.9 ± 0.2 0.90 2.0 ± 0.2 1.9 ± 0.2 0.01
BMI, kg/m2 26.6 ± 4.8 25.9 ± 3.4 0.01 26.0 ± 3.4 25.7 ± 3.2 0.03
Urinary excretion
2Py, µmol/day 178.1 (130.3–242.8) 155.6 (119.6–217.6) 0.001 152.8 (124.4–215.1) 161.7 (116.6–227.8) 0.31
N1-MN, µmol/day 22.0 (15.8–31.8) 41.4 (31.6–57.2) <0.001 40.9 (31.0–58.2) 32.5 (23.4–44.0) <0.001
2Py/N1-MN 8.7 ± 3.8 4.0 ± 1.4 <0.001 4.0 ± 1.4 5.2 ± 1.5 <0.001
Sum of 2Py and
N1-MN, µmol/day 198.3 (155.9–269.4) 203.7 (149.4–274.7) 0.98 198.3 (162.3–270.8) 189.7 (141.9–271.6) 0.90
2Py fraction, % 4 89.1 (86.4–91.3) 79.0 (75.6–82.1) <0.001 78.3 (75.5–81.8) 83.5 (80.0–86.0) <0.001
N1-MN fraction, % 4 10.9 (8.7–13.6) 21.0 (17.9–24.4) <0.001 21.7 (18.2–24.5) 16.5 (14.0–20.0) <0.001
Kidney function
eGFR, mL/min/1.73 m2 45.8 ± 18.7 91.0 ± 14.2 <0.001 92.8 ± 13.9 60.1 ± 12.1 <0.001
GFR, mL/min/1.73 m2 52.4 ± 17.4 82.3 ± 29.7 <0.001 103.7 ± 16.7 65.3 ± 10.4 <0.001
1 Data are presented as mean ± SD, median (IQR) and absolute number (percentage) for normally distributed, skewed and nominal data, respectively. 2 p-value for difference between
RTR and the total cohort of kidney donors was tested by t and Mann–Whitney tests for normally and skewed distributed continuous variables, respectively. 3 p-value for difference
between kidney donors before and after kidney donation was tested by paired samples t and Wilcoxon signed rank tests for normally and skewed distributed continuous variables,
respectively. 4 The urinary fraction of 2Py or N1-MN (percentage) was calculated by dividing 2Py or N1-MN excretion by the sum of 2Py and N1-MN excretion, respectively, and
multiplying by 100. BMI, body mass index; eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients;
2Py, N1-methyl-2-pyridone-5-carboxamide; 2Py/N1-MN, ratio of 2Py to N1-MN.
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Standardized β −0.39 −0.20 −0.02 0.15
p-value <0.001 0.003 0.89 0.27
1 Linear regression an lyses were performed to investigate associations of urinary 2Py/N1-MN with kidney function,
with adjustment for age and sex. eGFR, estimated glomerular filtration rate; GFR, glomerular filtration rate; N1-MN,
N1-methylnicotinamide; RTR, renal transplant recipients; 2Py, N1-methyl-2-pyridone-5-carboxamide; 2Py/N1-MN,
ratio of 2Py to N1-MN.
3.4. Characteristics and Associations with Urinary 2Py/N1-MN in RTR
Characteristics of the RTR cohort are shown in Table 3. Urinary 2Py/N1-MN was positively
associated with body surface area, body mass index (BMI), glucose homeostasis parameters,
triglycerides, mean arterial pressure, high-sensitivity C-reactive protein (hs-CRP), proteinuria, and
use of antidiabetics, antihypertensives, acetylsalicylic acid, proton pump inhibitors and tacrolimus.
Inverse associations were found between urinary 2Py/N1-MN and smoking, alcohol consumption,
energy intake, vitamin B6 intake, high-density lipoprotein (HDL) and eGFR.
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Table 3. Associations of urinary 2Py/N1-MN with characteristics in 660 RTR 1,2.
Variable Value Standardized β p-Value
Urinary 2Py/N1-MN 8.7 ± 3.8 - -
2Py excretion, µmol/day 178.1 (130.3–242.8) - -
N1-MN excretion, µmol/day 22.0 (15.8–31.8) - -
Age, years 53.0 ± 12.7 0.03 0.09
Male, n (%) 379 (57) −0.004 0.92
Body surface area, m2 1.9 ± 0.22 0.11 0.006
BMI, kg/m2 26.6 ± 4.8 0.17 <0.001
Creatinine excretion, mmol/day 11.7 ± 3.4 −0.05 0.22
Time since transplantation, years 5.6 (2.0–12.0) −0.07 0.07
Lifestyle
Current smoker, n (%) 78 (13) −0.10 0.02
Alcohol consumption, g/day 3.1 (0.0–11.9) −0.15 <0.001
Nutrition
Energy intake, kcal/day 2182 ± 642 −0.09 0.03
Niacin equivalents intake,
mg/day 35.6 ± 9.2 −0.06 0.14
Vitamin B6 intake, mg/day 1.8 ± 0.5 −0.09 0.03
Glucose homeostasis
Glucose, mmol/L 5.3 (4.8–6.0) 0.15 <0.001
HbA1c, % 5.8 (5.5–6.2) 0.12 0.002
Diabetes, n (%) 152 (23) 0.16 <0.001
Lipid homeostasis
Total cholesterol, mmol/L 5.1 ± 1.1 0.03 0.38
LDL, mmol/L 3.0 ± 0.9 0.07 0.10
HDL, mmol/L 1.3 (1.1–1.7) −0.20 <0.001
Triglycerides, mmol/L 1.7 (1.2–2.3) 0.17 <0.001
Hemodynamic
Systolic blood pressure, mmHg 135.8 ± 17.3 0.07 0.08
Diastolic blood pressure, mmHg 82.5 ± 11.0 0.08 0.05
Mean arterial pressure, mmHg 107.0 ± 15.0 0.10 0.02
Inflammation
Hs-CRP, mg/L 1.6 (0.7–4.6) 0.19 <0.001
Kidney function
eGFR, mL/min/1.73 m2 45.8 ± 18.7 −0.40 <0.001
Proteinuria, n (%) 132 (20) 0.08 0.04
Nonimmunosuppressive
medication
Antidiabetic, n (%) 96 (15) 0.14 <0.001
Statin, n (%) 349 (53) 0.06 0.15
Antihypertensive, n (%) 581 (88) 0.09 0.02
Acetylsalicylic acid, n (%) 127 (19) 0.09 0.03
Proton pump inhibitor, n (%) 326 (49) 0.08 0.04
Immunosuppressive medication
Prednisolon dose, mg/day 3.0 (2.0–3.0) 0.07 0.07
Proliferation inhibitor, n (%) 548 (83) −0.02 0.71
Tacrolimus, n (%) 120 (18) 0.11 0.007
Cyclosporine, n (%) 253 (38) −0.01 0.72
1 Data are presented as mean ± SD, median (IQR) and absolute number (percentage) for normally distributed,
skewed and nominal data, respectively. 2 Linear regression analyses were performed to investigate associations
of urinary 2Py/N1-MN with baseline variables, of which standardized β and p-value are presented. BMI, body
mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein;
hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; N1-MN, N1-methylnicotinamide; RTR,
renal transplant recipients; 2Py, N1-methyl-2-pyridone-5-carboxamide; 2Py/N1-MN, ratio of 2Py to N1-MN.
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3.5. Determinants of Urinary 2Py/N1-MN in RTR
Stepwise multivariable linear regression analyses with backward elimination revealed smoking,
alcohol consumption, diabetes, HDL, hs-CRP and eGFR as independent determinants of urinary
2Py/N1-MN in RTR (Table 4). In the final model, urinary 2Py/N1-MN was positively associated with
diabetes (β = 0.10; p = 0.01) and hs-CRP (β = 0.10; p = 0.009), and inversely associated with smoking
(β = −0.13; p = 0.001), alcohol consumption (β = −0.12; p = 0.002), HDL (β = −0.12; p = 0.002) and
eGFR (β = −0.38; p < 0.001).
Table 4. Independent determinants of urinary 2Py/N1-MN in RTR.
Variable
Univariable Multivariable 1
Standardized β p-Value Standardized β p-Value
Age, years 0.03 0.09 - -
Male, n (%) −0.004 0.92 - -
BMI, kg/m2 0.17 <0.001 - -
Time since transplantation, years −0.07 0.07 - -
Lifestyle
Current smoker, n (%) −0.10 0.02 −0.13 0.001
Alcohol consumption, g/day −0.15 <0.001 −0.12 0.002
Nutrition
Energy intake, kcal/day −0.09 0.03 - -
Niacin equivalents intake, mg/day −0.06 0.14 - -
Vitamin B6 intake, mg/day −0.09 0.03 - -
Glucose homeostasis
Diabetes, n (%) 0.16 <0.001 0.10 0.01
Lipid homeostasis
LDL, mmol/L 0.07 0.10 - -
HDL, mmol/L −0.20 <0.001 −0.12 0.002
Hemodynamic
Mean arterial pressure, mmHg 0.10 0.02 - -
Inflammation
Hs-CRP, mg/L 0.19 <0.001 0.10 0.009
Kidney function
eGFR, mL/min/1.73 m2 −0.40 <0.001 −0.38 <0.001
Proteinuria, n (%) 0.08 0.04 - -
Nonimmunosuppressive
medication
Antihypertensive, n (%) 0.09 0.02 - -
Acetylsalicylic acid, n (%) 0.09 0.03 - -
Proton pump inhibitor, n (%) 0.08 0.04 - -
Immunosuppressive medication
Prednisolon dose, mg/day 0.07 0.07 - -
Tacrolimus, n (%) 0.11 0.007 - -
R2 0.28 0.26
Adjusted R2 0.25 0.25
1 Stepwise multivariable linear regression with backward elimination was performed to identify determinants
of urinary 2Py/N1-MN, of which standardized β and p-value are presented. BMI, body mass index;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive
protein; LDL, low-density lipoprotein; N1-MN, N1-methylnicotinamide; RTR, renal transplant recipients; 2Py,
N1-methyl-2-pyridone-5-carboxamide; 2Py/N1-MN, ratio of 2Py to N1-MN.
J. Clin. Med. 2020, 9, 437 9 of 14
4. Discussion
This study aimed to investigate the 24-h urinary excretion of both 2Py and N1-MN as major
catabolic products of NAD+ with regard to kidney function. We assessed 2Py and N1-MN excretion in
RTR and healthy kidney donors as a model of renal disease, and in kidney donors before and after
unilateral nephrectomy as a model of isolated renal function impairment. In RTR, 2Py excretion was
significantly higher compared to that in kidney donors. Urinary 2Py/N1-MN increased significantly in
kidney donors after donation. In both RTR and kidney donors, urinary 2Py/N1-MN was associated
with kidney function. Kidney function was furthermore revealed as the strongest determinant of
urinary 2Py/N1-MN in RTR.
NAD+ is formed either de novo from tryptophan via the kynurenine pathway, or via salvage
pathways from preformed nicotinamide, nicotinic acid and nicotinamide riboside [26], commonly
known as niacin, or vitamin B3. NAD+ catabolism proceeds via nicotinamide and its downstream
metabolites N1-MN and 2Py, respectively (Figure 1), and these products are found in both plasma and
urine [27]. N1-MN itself exhibits anti-inflammatory properties, and is produced by muscle in response
to hypoxia and depletion of energy stores, besides its primary production in the liver [28]. Whereas
nicotinamide is reabsorbed by renal tubules and only small amounts appear in urine, N1-MN and 2Py
account for 20%–35% and 45%–60%, respectively, of all urinary NAD+ metabolites [29]. The WHO
and the EFSA recommend the 24-h urinary excretion of N1-MN for laboratory assessment of niacin
nutritional status accordingly [3,4]. In a previous study, we found that N1-MN excretion is clearly
reduced in RTR compared to healthy kidney donors [12]. The fact that this is paralleled by a significant
elevation of 2Py excretion in the present study, raises speculation that enhanced enzymatic conversion
of N1-MN to 2Py by AOX1 may be present in RTR. Furthermore, the opposing shifts of 2Py and N1-MN
excretion in kidney donors after donation, may imply a putative isolated effect of renal function
impairment on urinary 2Py/N1-MN.
Regarding kidney function, urinary 2Py/N1-MN was positively associated with kidney function
in both RTR and the total cohort of kidney donors. Renal clearance of N1-MN is affected by lower
kidney function [13,14], being freely filtered at the glomerulus and tubular secreted, with negligible
and saturable tubular reabsorption [30,31]. 2Py has previously been classified as a uremic retention
product by the European Uremic Toxin Working Group [32,33], though specific mechanisms of its
renal clearance have yet not been characterized. Whereas plasma concentrations of 2Py are reported
to increase progressively with chronic kidney disease stages [34], those of N1-MN are suggested to
be less sensitive to kidney function because of the contribution of AOX1 to N1-MN clearance [13,14].
In view of this, we can speculate upon slower excretion of N1-MN, hence prolonged exposure to
2Py-forming AOX1 that is related to kidney function, rather than retention of 2Py primarily. This
speculation is supported by the fact that kidney function appeared to have only a minor effect on the
daily excretion of the sum of 2Py and N1-MN in all groups. The presence of a significant association of
urinary 2Py/N1-MN with kidney function in the total cohort of kidney donors, but not in the pre- and
post-donation subgroups, is most likely due to smaller effect sizes in the latter subgroups of kidney
donors being declared eligible after pre-donation screening.
The identification of eGFR as the strongest independent determinant of urinary 2Py/N1-MN in
RTR further supports the notion of an isolated effect of kidney function. Other identified determinant
factors include those that are known to affect the enzymatic activity of the aforementioned 2Py-forming
AOX1 and most likely contribute as such. In fact, urinary 2Py/N1-MN has been used as an index to
estimate in vivo AOX1 levels and activity [35], being regulated by a wide variety of endogenous and
exogenous factors [36]. Smoking and alcohol consumption are well-known factors [37,38] that showed
an inverse association with urinary 2Py/N1-MN in RTR. Diabetes and inflammatory mediators [37],
including hs-CRP [39,40], have also been implicated in AOX1 activity, as well as HDL-cholesterol-levels
via interaction of AOX1 with the ATP-binding cassette transporter A1 (ABCA1) which is a regulator of
HDL metabolism [41,42]. Surprisingly, medication use did not appear to affect urinary 2Py/N1-MN in
RTR, despite the significant function of AOX1 in metabolizing xenobiotics. Importantly, the fact that
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urinary 2Py/N1-MN has multiple determinants in addition to eGFR, precludes its use as a biomarker
of kidney function.
Excessive poly (ADP-ribose) polymerase (PARP) activation induced by stressors such as
inflammation, oxidative stress and DNA damage that are predominant in RTR [43,44], has also
been implicated in higher production of 2Py from NAD+ degradation [45,46]. One would, however,
expect that this would be reflected by an overall increase of NAD+ catabolites, which is opposed by
the two-fold reduction of N1-MN excretion in our RTR population.
In general, higher urinary output of NAD+ metabolites indicates higher niacin nutritional status,
being excreted after the pool of pyridine nucleotide coenzymes is filled [47]. Acute stress may alter
this output, but not steady state conditions, in which elimination and production rates are equal [48].
However, the ratio of metabolites is subject to factors that affect not only the activity of 2Py-forming
AOX1, but according to our data also kidney function. In a previous study, we found N1-MN excretion
to be lower in RTR independent of dietary intake of niacin equivalents, as well as to be positively
associated with kidney function [12]. According to the present study, the latter association remains
when taking into account 2Py excretion, by means of urinary 2Py/N1-MN. Therefore, although urinary
excretion of N1-MN is the most common and recommended index [3,4], our findings suggest that
this index might be of limited value in conditions of kidney function impairment and future studies
may confirm whether 2Py excretion should at least be additionally interpreted for evaluation of niacin
nutritional status.
The speculative presence of slower excretion, hence prolonged exposure of N1-MN to 2Py-forming
AOX1 with kidney function impairment has not been confirmed in previous studies. In fact, this
speculation indicates straight substrate conversion kinetics, which is unlikely to fully account for the
previously reported, increased serum concentrations of 2Py in patients with chronic renal failure [46].
More specifically, Rutkowski et al. suggested high serum concentrations of 2Py in chronic renal
failure to be a result of kidney function impairment, based on the fact that serum concentrations
of 2Py were approximately 20-fold higher in patients with advanced renal failure than in healthy
subjects (15.5 ± 5.8 µmol/L versus 0.83 ± 0.18 µmol/L), with only a transient drop after dialysis, and a
permanent reduction after kidney transplantation [46]. Accordingly, given its accumulation, along
with a deterioration of kidney function, and its toxic properties due to significant inhibition of PARP
activity, 2Py has been identified as a uremic toxin [32,45,46]. As we only measured urinary excretion
of 2Py, it cannot be ruled out whether increased urinary excretion of 2Py is solely the consequence
of increased serum concentrations of 2Py, due to decreased renal clearance, rather than conversion
kinetics of N1-MN to 2Py by AOX1, and future studies are warranted to address this matter.
Strengths of this study include the large sample size of a specific patient group and the availability
of healthy kidney donors before donation as a control group, and after donation as a model of isolated
renal function impairment. Moreover, the extensive characterization of RTR allowed us to control for
other factors that could affect 2Py/N1-MN in 24-h urine, and to comprehensively identify determinants
of urinary 2Py/N1-MN. The ratio of metabolites in 24-h urine provides a measure to demonstrate
changes in metabolism related to renal function, while being the least sensitive to 24-h urine collection
errors. Limitations of this study are its observational nature, which prohibits causal inferences, as well
as final conclusions on underlying mechanisms of increased urinary 2Py/N1-MN in RTR and kidney
donors after kidney donation, and associations with kidney function. Therefore, it remains to be
determined whether the association of urinary 2Py/N1-MN with kidney function is a causal relation.
The observational design of this study did neither allow us to rule out increased serum concentrations
of 2Py due to decreased renal clearance, or higher production of 2Py from NAD+ degradation due to
PARP activation by means of an experimental design. Conclusions are yet additionally supported
by the presence of direct associations of the 24-h urinary excretion of 2Py, N1-MN, and the sum
of 2Py and N1-MN, but not urinary 2Py/N1-MN, with niacin nutritional intake (Table S1). Future
studies are strongly encouraged to elaborate on serum concentrations of 2Py and N1-MN along with
their urinary excretion. The present study is confined to the urinary excretion of the major NAD+
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metabolites, comprising the most common and recommended indices of niacin nutritional status
according to existing literature and authorities, including the WHO and the EFSA [3,4], respectively.
Other indices, including serum or erythrocyte concentrations of niacin and its metabolites [49], are
considered inferior as urinary concentrations have shown the most sensitive response to oral test doses
of niacin equivalents [3,7]. Given the aforementioned limitations, this study should be conceived
as a descriptive report that precludes final conclusions on the applicability of N1-MN excretion as a
biomarker of niacin nutritional status in conditions of impaired kidney function. Finally, although
niacin deficiency is considered to be uncommon in the developed world, it might be prevalent in
subpopulations, including RTR [12]. Still, it should be emphasized that assessment of niacin nutritional
status might not be feasible in the developing world given the costs.
5. Conclusions
The 24-h urinary excretion of 2Py is higher in RTR than in kidney donors, and urinary 2Py/N1-MN
clearly increases after kidney donation. Urinary 2Py/N1-MN is associated with kidney function in
both RTR and kidney donors, and kidney function is identified as the strongest determinant of urinary
2Py/N1-MN in RTR. Therefore, interpretation of both N1-MN and 2Py excretion, rather than N1-MN
alone, may be recommended for assessment of niacin nutritional status in conditions of impaired
kidney function.
Supplementary Materials: The following is available online at http://www.mdpi.com/2077-0383/9/2/437/s1, Table
S1: Associations of 2Py and N1-MN excretion with niacin equivalents intake in RTR and kidney donors.
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